MARKET

RLAY

RLAY

Relay Therapeutics, Inc.
NASDAQ
10.55
-0.25
-2.31%
Pre Market: 10.63 +0.08 +0.76% 07:36 03/13 EDT
OPEN
10.73
PREV CLOSE
10.80
HIGH
10.85
LOW
10.15
VOLUME
2.24K
TURNOVER
0
52 WEEK HIGH
11.43
52 WEEK LOW
1.775
MARKET CAP
1.89B
P/E (TTM)
-6.5475
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Stryker (SYK) and Elutia (ELUT)
TipRanks · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY)
TipRanks · 1d ago
Relay Therapeutics Updates Bylaws on Federal Securities Litigation
TipRanks · 1d ago
Relay Therapeutics Adopts Federal Court Exclusive Forum Bylaw for Securities Act Claims
Reuters · 1d ago
Weekly Report: what happened at RLAY last week (0302-0306)?
Weekly Report · 4d ago
Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst
Seeking Alpha · 03/05 10:42
Weekly Report: what happened at RLAY last week (0223-0227)?
Weekly Report · 03/02 09:55
Relay Therapeutics Shares Hit 52-Week High After Higher 4Q Revenue
Dow Jones · 02/27 18:06
More
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Webull offers Relay Therapeutics Inc stock information, including NASDAQ: RLAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLAY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLAY stock methods without spending real money on the virtual paper trading platform.